$11.61
+0.13
(+1.13%)▲
0.95%
Downside
Day's Volatility :1.67%
Upside
0.73%
11.89%
Downside
52 Weeks Volatility :32.48%
Upside
23.37%
Period | Dynavax Technologies Corporation | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 2.41% | 6.5% | 0.0% |
6 Months | -13.81% | 7.1% | 0.0% |
1 Year | -19.33% | 9.8% | 0.0% |
3 Years | 23.71% | 14.2% | -20.2% |
Market Capitalization | 1.5B |
Book Value | $4.73 |
Earnings Per Share (EPS) | 0.07 |
PE Ratio | 164.0 |
PEG Ratio | 0.0 |
Wall Street Target Price | 25.75 |
Profit Margin | 3.9% |
Operating Margin TTM | -38.14% |
Return On Assets TTM | -1.35% |
Return On Equity TTM | 1.56% |
Revenue TTM | 236.1M |
Revenue Per Share TTM | 1.83 |
Quarterly Revenue Growth YOY | 8.200000000000001% |
Gross Profit TTM | 448.2M |
EBITDA | -16.7M |
Diluted Eps TTM | 0.07 |
Quarterly Earnings Growth YOY | -0.76 |
EPS Estimate Current Year | 0.17 |
EPS Estimate Next Year | 0.4 |
EPS Estimate Current Quarter | -0.02 |
EPS Estimate Next Quarter | 0.09 |
What analysts predicted
Upside of 121.79%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 8.2M | ↑ 2407.03% |
Net Income | -158.9M | ↑ 66.99% |
Net Profit Margin | -1.9K% | ↑ 27160.81% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 35.2M | ↑ 329.6% |
Net Income | -151.4M | ↓ 4.72% |
Net Profit Margin | -429.87% | ↑ 1508.4% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 46.6M | ↑ 32.18% |
Net Income | -91.8M | ↓ 39.38% |
Net Profit Margin | -197.15% | ↑ 232.72% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 439.4M | ↑ 844.0% |
Net Income | 76.7M | ↓ 183.59% |
Net Profit Margin | 17.46% | ↑ 214.61% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 722.7M | ↑ 64.45% |
Net Income | 293.2M | ↑ 282.15% |
Net Profit Margin | 40.56% | ↑ 23.1% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 232.3M | ↓ 67.86% |
Net Income | -6.4M | ↓ 102.18% |
Net Profit Margin | -2.75% | ↓ 43.31% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 184.5M | ↑ 9.99% |
Net Income | 67.7M | ↑ 6.15% |
Net Profit Margin | 36.71% | ↓ 1.33% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 46.9M | ↓ 74.57% |
Net Income | -24.3M | ↓ 135.92% |
Net Profit Margin | -51.85% | ↓ 88.56% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 60.2M | ↑ 28.39% |
Net Income | 3.4M | ↓ 114.1% |
Net Profit Margin | 5.69% | ↑ 57.54% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 69.5M | ↑ 15.38% |
Net Income | 14.3M | ↑ 316.58% |
Net Profit Margin | 20.56% | ↑ 14.87% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 55.6M | ↓ 20.02% |
Net Income | 219.0K | ↓ 98.47% |
Net Profit Margin | 0.39% | ↓ 20.17% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 50.8M | ↓ 8.64% |
Net Income | -8.7M | ↓ 4082.19% |
Net Profit Margin | -17.17% | ↓ 17.56% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 210.9M | ↓ 3.61% |
Total Liabilities | 147.8M | ↑ 668.45% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 279.1M | ↑ 32.33% |
Total Liabilities | 270.8M | ↑ 83.18% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 353.3M | ↑ 26.59% |
Total Liabilities | 294.6M | ↑ 8.79% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.0B | ↑ 194.18% |
Total Liabilities | 816.9M | ↑ 177.3% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 985.9M | ↓ 5.14% |
Total Liabilities | 404.8M | ↓ 50.44% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 997.1M | ↑ 1.14% |
Total Liabilities | 375.0M | ↓ 7.36% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 985.9M | ↓ 1.35% |
Total Liabilities | 404.8M | ↓ 18.83% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 969.9M | ↓ 1.62% |
Total Liabilities | 406.2M | ↑ 0.33% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 936.4M | ↓ 3.45% |
Total Liabilities | 359.2M | ↓ 11.56% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 972.9M | ↑ 3.9% |
Total Liabilities | 368.0M | ↑ 2.45% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 997.1M | ↑ 2.48% |
Total Liabilities | 375.0M | ↑ 1.9% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 986.6M | ↓ 1.06% |
Total Liabilities | 368.1M | ↓ 1.85% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -131.3M | ↑ 69.38% |
Investing Cash Flow | 55.5M | ↓ 151.03% |
Financing Cash Flow | 99.1M | ↓ 47.26% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -121.3M | ↓ 7.65% |
Investing Cash Flow | -42.8M | ↓ 177.13% |
Financing Cash Flow | 154.4M | ↑ 55.8% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -92.3M | ↓ 23.92% |
Investing Cash Flow | -26.5M | ↓ 37.98% |
Financing Cash Flow | 109.5M | ↓ 29.06% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 335.5M | ↓ 463.71% |
Investing Cash Flow | 14.2M | ↓ 153.61% |
Financing Cash Flow | 55.8M | ↓ 49.06% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 62.7M | ↓ 81.31% |
Investing Cash Flow | -316.0M | ↓ 2321.41% |
Financing Cash Flow | 19.5M | ↓ 64.99% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 34.9M | ↓ 43.23% |
Investing Cash Flow | -33.0M | ↓ 72.31% |
Financing Cash Flow | 153.0K | ↓ 98.1% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 27.6M | ↓ 20.96% |
Investing Cash Flow | -52.3M | ↑ 58.75% |
Financing Cash Flow | -3.1M | ↓ 2119.61% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 28.0M | ↑ 1.54% |
Investing Cash Flow | 24.7M | ↓ 147.24% |
Financing Cash Flow | -294.0K | ↓ 90.49% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 31.1M | ↑ 10.99% |
Investing Cash Flow | -106.1M | ↓ 529.07% |
Financing Cash Flow | 3.0M | ↓ 1118.37% |
Sell
Neutral
Buy
Dynavax Technologies Corporation is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Dynavax Technologies Corporation | 4.17% | -13.81% | -19.33% | 23.71% | 41.55% |
![]() Neurocrine Biosciences Inc. | 7.56% | 2.78% | 45.55% | 52.55% | 67.01% |
![]() Haleon Plc Spon Ads | 7.53% | 11.87% | 3.28% | 23.35% | 23.35% |
![]() Zoetis Inc. | 5.77% | -5.62% | -5.85% | -9.99% | 57.03% |
![]() Viatris Inc. | 12.75% | -1.42% | 12.21% | -15.03% | -28.03% |
![]() Catalent, Inc. | 4.08% | 11.91% | 19.53% | -48.27% | 2.08% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Dynavax Technologies Corporation | 164.0 | 164.0 | 0.0 | 0.17 | 0.02 | -0.01 | NA | 4.73 |
![]() Neurocrine Biosciences Inc. | 39.75 | 39.75 | 0.44 | 3.99 | 0.18 | 0.1 | NA | 23.72 |
![]() Haleon Plc Spon Ads | 29.9 | 29.9 | 1.69 | 0.39 | 0.07 | 0.04 | 0.02 | 1.8 |
![]() Zoetis Inc. | 34.62 | 34.62 | 2.58 | 5.77 | 0.5 | 0.14 | 0.01 | 11.07 |
![]() Viatris Inc. | 224.4 | NA | 0.06 | 2.73 | 0.0 | 0.03 | 0.04 | 16.81 |
![]() Catalent, Inc. | 211.02 | NA | 2.06 | 0.2 | -0.28 | -0.01 | NA | 19.96 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Dynavax Technologies Corporation | Buy | $1.5B | 41.55% | 164.0 | 3.9% |
![]() Neurocrine Biosciences Inc. | Buy | $14.7B | 67.01% | 39.75 | 18.65% |
![]() Haleon Plc Spon Ads | Buy | $41.0B | 23.35% | 29.9 | 9.64% |
![]() Zoetis Inc. | Buy | $82.0B | 57.03% | 34.62 | 27.38% |
![]() Viatris Inc. | Hold | $14.2B | -28.03% | 224.4 | -0.37% |
![]() Catalent, Inc. | Hold | $10.6B | 2.08% | 211.02 | -28.44% |
Insights on Dynavax Technologies Corporation
Revenue is down for the last 3 quarters, 69.51M → 50.79M (in $), with an average decrease of 14.3% per quarter
Netprofit is down for the last 3 quarters, 14.29M → -8.72M (in $), with an average decrease of 2090.3% per quarter
In the last 1 year, Neurocrine Biosciences Inc. has given 45.5% return, outperforming this stock by 64.8%
In the last 3 years, Neurocrine Biosciences Inc. has given 52.6% return, outperforming this stock by 28.9%
BlackRock Inc
State Street Corporation
Vanguard Group Inc
Deep Track Capital, LP
Federated Hermes Inc
Chicago Capital, LLC
dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.
Organization | Dynavax Technologies Corporation |
Employees | 408 |
CEO | Mr. Ryan Spencer |
Industry | Health Technology |
A Spac I Acquisition Corp
$11.61
+1.13%
Keyarch Acquisition Corp
$11.61
+1.13%
Connexa Sports Technologies Inc
$11.61
+1.13%
Us Value Etf
$11.61
+1.13%
First Wave Biopharma Inc
$11.61
+1.13%
Global X Msci Next Emerging
$11.61
+1.13%
Fat Projects Acquisition Corp
$11.61
+1.13%
Capital Link Global Fintech
$11.61
+1.13%
Applied Uv Inc
$11.61
+1.13%